Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Xofluza (Shionogi)
- INDICATIONS: Indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
- CLASS: Polymerase acidic (PA) endonuclease inhibitor
- HALF-LIFE: 79.1 hours
- FDA APPROVAL DATE: 10/24/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Calcium Hydroxylapatite, Selenium, Zinc - PREGNANCY: no available data
Please login to view the rest of this drug profile.
Page last updated 08/20/2023
